465 related articles for article (PubMed ID: 19159435)
21. Imatinib: a targeted clinical drug development.
Capdeville R; Silberman S
Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
[TBL] [Abstract][Full Text] [Related]
22. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
Zhang P; Gao WY; Turner S; Ducatman BS
Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
[TBL] [Abstract][Full Text] [Related]
23. [Imatinib induces c-kit positive myeloma cells apoptosis].
Li J; Huang BH; Zhao Y; Luo SK
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):230-3. PubMed ID: 18843975
[TBL] [Abstract][Full Text] [Related]
24. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
Catalano MG; Pugliese M; Poli R; Bosco O; Bertieri R; Fortunati N; Boccuzzi G
Oncol Rep; 2009 Feb; 21(2):515-21. PubMed ID: 19148530
[TBL] [Abstract][Full Text] [Related]
25. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
26. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells.
Basciani S; Vona R; Matarrese P; Ascione B; Mariani S; Cauda R; Gnessi L; Malorni W; Straface E; Lucia MB
FEBS Lett; 2007 Dec; 581(30):5897-903. PubMed ID: 18061581
[TBL] [Abstract][Full Text] [Related]
27. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract][Full Text] [Related]
28. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
Hägerstrand D; Hesselager G; Achterberg S; Wickenberg Bolin U; Kowanetz M; Kastemar M; Heldin CH; Isaksson A; Nistér M; Ostman A
Oncogene; 2006 Aug; 25(35):4913-22. PubMed ID: 16547494
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
30. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
[TBL] [Abstract][Full Text] [Related]
31. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice.
Nakagawa H; Takiguchi T; Nakamura M; Furuyama A; Koyanagi S; Aramaki H; Higuchi S; Ohdo S
Biochem Pharmacol; 2006 Nov; 72(10):1237-45. PubMed ID: 16973134
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
Kawamoto T; Akisue T; Marui T; Nakatani T; Hitora T; Fujita I; Kurosaka M; Yamamoto T
Anticancer Res; 2004; 24(5A):2675-9. PubMed ID: 15517872
[TBL] [Abstract][Full Text] [Related]
34. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
[TBL] [Abstract][Full Text] [Related]
36. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM.
Lin CK; Nguyen TT; Morgan TL; Mei RL; Kaptein JS; Kalunta CI; Yen CF; Park E; Zou HY; Lad PM
Exp Cell Res; 1998 Oct; 244(1):1-13. PubMed ID: 9770343
[TBL] [Abstract][Full Text] [Related]
38. cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib.
Bianchini M; Martinelli G; Renzulli M; Gonzalez Cid M; Larripa I
Cancer Chemother Pharmacol; 2007 Feb; 59(3):349-60. PubMed ID: 17009037
[TBL] [Abstract][Full Text] [Related]
39. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA.
Le Jeune N; Dubois F; Bin V; Perek N
Eur J Cancer; 2006 May; 42(8):1004-13. PubMed ID: 16564690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
